The Week In Cannabis: Charlotte Figi's Passing, Epidiolex's De-Scheduling, Stocks Up And More

The Week In Cannabis: Charlotte Figi's Passing, Epidiolex's De-Scheduling, Stocks Up And More

A shortened week came with a no shortage of news for the cannabis community and industry.We must start with a deeply sad event: the passing of 13-year-old Charlotte Figi in the hands of COVID-19.Charlotte had become a face for the cannabis legalization movement after Colorado cannabis growers, the Stanley brothers, developed a strain of marijuana that was high on CBD and very low on THC, to help her parents treat her very rare form of epilepsy, Dravet syndrome. In a heartbreaking post, the Stanley brothers described Charlotte's bravery: "Charlotte was ten feet tall and carried the world on her shoulders."But it seems her activism was not in vain, for this week we learned the U.S. Drug Enforcement Administration descheduled GW Pharmaceuticals plc's (NASDAQ: GWPH) Epidiolex, a cannabinoid-containing drug that is used to treat Lennox-Gastaut Syndrome and Dravet syndrome. This came only days after the FDA granted the same drug Priority Review...

Notable Insider Buys In The Past Week: Carnival, MGM And More

* Insider buying can be an encouraging signal for potential investors. * Some insiders made return trips to the buy window last week. * Cruise line and resort operators were among those that saw notable insider buying.Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly during periods of uncertainty.Insiders continued to take advantage of fallen share prices last week. Here are some of the most noteworthy insider purchases reported in the past week.A director took advantage of a common stock offering to add 1.25 million Carnival Corp (NYSE: CCL) shares. At a share price of $8.00, that cost the director $10.00 million. The stock ended last week's trading at $12.42 per share, which is up...

Johnson Released; Spanish, German Cases Decline: Virus Update

(Bloomberg) -- U.K. Prime Minister Boris Johnson was released from the hospital after being treated for Covid-19 for a week. The U.S. became the world’s epicenter for coronavirus as deaths passed Italy.China said more than half of the country’s 99 new cases were passengers on a plane that flew to Shanghai from Russia. Singapore threatened immediate fines on people who flout social-distancing rules and Indonesia imposed tighter measures on the outskirts of Jakarta, while Iran plans to lift a ban on travel between provinces.U.K. banks are stepping up loans to help businesses with the economic fallout from the pandemic, and the Trump administration said it’s on track to roll out the diagnostics needed to determine when normal activities can resume.Key DevelopmentsCoronavirus Tracker: Global cases exceed 1.78 million; deaths top 109,000U.S. deaths reach 20,600Spain cases keep slowing, deaths approach 17,000China reports 99 new cases from April 11, 97 of which are importedU.S....

Microsoft’s Bill Gates to Spend Billions of Dollars on Coronavirus Vaccine Development

Microsoft Corp.’s (MSFT) co-founder Bill Gates said his foundation will invest billions of dollars on the construction of factories with the aim of developing a coronavirus vaccine.The billionaire philanthropist disclosed that the Bill and Melinda Gates Foundation will be selecting the top seven vaccine candidates. Even though the foundation will end up picking at most two of them, it is going to fund factories for all seven.“It will be a few billion dollars we’ll waste on manufacturing for the constructs that don’t get picked because something else is better,” Gates told Trever Noah on The Daily Show. “But a few billion in this, the situation we’re in, where there’s trillions of dollars … being lost economically, it is worth it.”Gates believes that therapeutic treatments of coronavirus-infected individuals could begin to roll out in four to six months, but it would take at least 18 months to develop a safe and effective...